Date: 2015-07-15
Type of information: Nomination
Compound: chairman of the board of directors
Company: Rigontec (Germany)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 15, 2015, Rigontec, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announced that Dr. J. Donald (Don) deBethizy has been appointed as Chairman of the Board of Directors. He replaces outgoing Chairman Prof. Dr. Gunther Hartmann who co-founded Rigontec and led the Board since 2014. Prof. Hartmann will remain on the Board of Directors.
- Dr. deBethizy brings more than 30 years of experience in research and development, as well as financial and operational management in the biotechnology and consumer products industry. He is currently President of White City Consulting ApS in Denmark and serves on the supervisory boards of arGEN-X NV (Euronext Brussels), Newron Pharmaceuticals SPA (SIX Swiss Exchange), Serendex Pharmaceuticals (Oslo Exchange) and Noxxon Pharma AG. Previously, Dr. deBethizy served as President and CEO of Santaris Pharma A/S until the company was sold to Roche, and as Executive Chairman of Contera Pharma until it was sold to Bukwang Pharma in November 2014. He was also co-founder and CEO of Targacept, Inc., a public US biotechnology company listed on NASDAQ. He recently served on the supervisory boards of LigoCyte Pharma, Enbiotix and Biosource.
- Dr. deBethizy holds MS and PhD degrees in toxicology from Utah State University and a BS in biology from the University of Maryland. He completed a postdoctoral fellowship at the Chemical Industry Institute of Toxicology at Research Triangle Park, NC, and is a Diplomat of the American Board of Toxicology.
Financial terms:
Latest news:
Is general: Yes
